Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 901751-47-1 Chemical Structure| 901751-47-1

Structure of iCRT3
CAS No.: 901751-47-1

Chemical Structure| 901751-47-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

iCRT3 can inhibit both Wnt and β-catenin-responsive transcription.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of iCRT3

CAS No. :901751-47-1
Formula : C23H26N2O2S
M.W : 394.53
SMILES Code : O=C(NCCC1=CC=CC=C1)CSCC2=C(C)OC(C3=CC=C(CC)C=C3)=N2
MDL No. :MFCD14766288
InChI Key :QTDYVSIBWGVBKU-UHFFFAOYSA-N
Pubchem ID :6622273

Safety of iCRT3

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H315-H318-H335
Precautionary Statements:P261-P280-P305+P351+P338
Class:8
UN#:3259
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT116 cells 50 μM 1 day To validate the inhibitory effect of iCRT3 on Wnt target genes, iCRT3 significantly inhibited AXN2 and CYCD1 mRNA expression PMC3076864
mouse embryonic stem cells (mESCs) 10 µM 14 days iCRT3 treatment enhanced the expression of pluripotency markers and reduced the expression of differentiation markers in mESCs. PMC4602028
hCMEC/D3 20 µM 15 hours iCRT3 inhibited the binding of β-catenin to the transcription factor TCF-4 in hCMEC/D3 cells, resulting in significant reductions in the mRNA expression of claudin-3, claudin-5, Pgp, and BCRP, and decreased monolayer electrical impedance, indicating reduced tight junction integrity. PMC6928218
Drosophila Cl8 cells 9 ng/μL 16 hours To screen for inhibitors of the Wnt/β-catenin signaling pathway, iCRT3 significantly inhibited dTF12 reporter activity PMC3076864
A549 cells 5 μM 24 hours iCRT3 significantly decreased the expression of LH3, Wnt1, β-catenin, and p-Smad3 proteins, and reduced collagen pyridine-crosslinking production. PMC7069430
mouse embryonic stem cells (mESCs) 10 µM 48 hours iCRT3 treatment reduced RA-induced differentiation and enhanced the expression of pluripotency markers. PMC4602028
C1.1 cells 10 μM 48 hours To investigate the effect of iCRT3 on TGF-β-induced cell migration and collagen expression. Results showed that iCRT3 combined with TGF-β significantly increased β-catenin/Foxo interaction, reduced β-catenin/TCF interaction, and decreased TGF-β-induced collagen expression. PMC8351131
PLC/PRF/5 cells 200 μM 48 hours iCRT3 repressed the protein levels of TCF1, Survivin and PRC1 PMC6182221
BT-549 25, 50, 75 μM 48 hours iCRT-3 effectively inhibits cell proliferation in BT-549 cells in a dose- and time-dependent manner. PMC4228255
MDA-MB-231 25, 50, 75 μM 48 hours iCRT-3 effectively inhibits cell proliferation in MDA-MB-231 cells in a dose- and time-dependent manner. PMC4228255
HCC-1143 25, 50, 75 μM 48 hours iCRT-3 effectively inhibits cell proliferation in HCC-1143 cells in a dose- and time-dependent manner. PMC4228255
HCC-1937 25, 50, 75 μM 48 hours iCRT-3 effectively inhibits cell proliferation in HCC-1937 cells in a dose- and time-dependent manner. PMC4228255
RAW264.7 macrophages 12.5, 25, 50, 75 μM 50 minutes pretreatment followed by 4 hours LPS stimulation iCRT3 significantly reduces LPS-induced Wnt/β-catenin activity and inhibits TNF-α production and IκB degradation in a dose-dependent manner. PMC5569053
HEK293 cells 25 μM To validate the inhibitory effect of iCRT3 on the Wnt signaling pathway, iCRT3 significantly inhibited STF16 reporter activity PMC3076864

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCT116 and HT29 xenograft models Intraperitoneal injection 50 mg/kg Three times a week for 3 weeks To validate the anti-tumor effect of iCRT14 in vivo, iCRT14 significantly inhibited tumor growth PMC3076864
C57BL/6 mice Unilateral renal ischemia reperfusion injury model Intraperitoneal injection 10 mg/kg Daily for 7 or 14 days To investigate the protective effect of iCRT3 on renal ischemia-reperfusion injury. Results showed that iCRT3 combined with TGF-β significantly increased β-catenin/Foxo interaction, reduced kidney fibrosis, and promoted tubular epithelial repair. PMC8351131
C57BL/6 mice cecal ligation and puncture (CLP)-induced sepsis model intraperitoneal injection 5 and 10 mg/kg single dose, administered 5 hours after CLP iCRT3 treatment significantly reduces plasma levels of proinflammatory cytokines and organ injury markers, and improves histological integrity of lung tissue, reducing lung collagen deposition and apoptosis. PMC5569053

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.67mL

2.53mL

1.27mL

25.35mL

5.07mL

2.53mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories